COMMUNIQUÉS West-GlobeNewswire

EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
04/02/2019
- YUTIQ Indicated for the Treatment of Chronic Non-Infectious Posterior Segment Uveitis - WATERTOWN, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical [...]
Northeast Scientific celebrates medical device remanufacturing success with a major reinvestment to bring its marketing, sales and customer service in-house
04/02/2019
WATERBURY, Conn., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Northeast Scientific, Inc. (NES), known for its advanced medical device remanufacturing successes for more than 13 years, continues its business growth and development [...]
Anavex Life Sciences to Present at the 2019 BIO CEO & Investor Conference
04/02/2019
NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]
Radient Technologies Inc. Receives Standard Processing License from Health Canada
04/02/2019
EDMONTON, Alberta, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI; OTCQX: RDDTF ) is pleased to announce it has received its Standard Processing License from [...]
Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994
04/02/2019
CAMBRIDGE, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in [...]
Canopy Rivers Announces Completion of $17 Million Financing for Its Italian Hemp Platform - Canapar
04/02/2019
TORONTO, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (the “ Company ” or “ Canopy Rivers ”) (TSXV: RIV) is pleased to announce that it has completed a subsequent $9.4 million equity investment in its portfolio [...]
Radient Technologies Inc. Announces Changes to its Board of Directors and Provides Corporate Update
04/02/2019
EDMONTON, Alberta, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI; OTCQX: RDDTF ) announces today the following changes to its Board of Directors. The Company [...]
Evolus to Hold Conference Call Following Jeuveau™ FDA Approval
04/02/2019
Conference Call Scheduled for at 8:00am ET / 5:00am PT NEWPORT BEACH, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), today announced that members of management will host a conference call today, [...]
Fennec Pharmaceuticals Announces $12.5 Million Debt Financing With Bridge Bank
04/02/2019
RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of [...]
Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra’s Dermatology Product Portfolio
04/02/2019
LAVAL, Quebec, and ORLEANS, Ontario, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Crescita Therapeutics Inc. ("Crescita") (TSX: CTX), a Canadian commercial dermatology company and Tetra Natural Health (NHP), a subsidiary of Tetra [...]
Orion intents to start an open label extension study to the REFALS phase 3 trial studying the effect of oral levosimendan in patients with ALS
04/02/2019
Orion Corporation Press release 4 February 2019 at 10.00 a.m. EET Orion intents to start an open label extension study to the REFALS phase 3 trial studying the effect of oral levosimendan in patients with ALS Orion [...]
Aino Health AB (publ): Aino Health's solution go-live for Multi Contact GmbH
04/02/2019
2019-02-04 Aino Health go-live with its SaaS solution Aino HealthManager for Multi Contact's operations in Germany. This is a joint implementation project with MultiContact and Aino Health that is comprised of process [...]
Aino Health AB (publ): Aino Health's solution go-live for Multi Contact GmbH
04/02/2019
2019-02-04 Aino Health go-live with its SaaS solution Aino HealthManager for Multi Contact's operations in Germany. This is a joint implementation project with MultiContact and Aino Health that is comprised of process [...]
Aino Health AB (publ): Aino Health's solution go-live for Multi Contact GmbH
04/02/2019
2019-02-04 Aino Health go-live with its SaaS solution Aino HealthManager for Multi Contact's operations in Germany. This is a joint implementation project with MultiContact and Aino Health that is comprised of process [...]
Oxurion NV to Present at the 2019 BIO CEO & Investor Conference
04/02/2019
Leuven, Belgium, 4 February 2019 - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced [...]
Verona Pharma to Present at Upcoming Investor Conferences
04/02/2019
LONDON, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
Curetis’ Partner Beijing Clear Biotech Submits Filing for Unyvero Approval in China
04/02/2019
Curetis’ Partner Beijing Clear Biotech Submits Filing for Unyvero Approval in China Submission for Unyvero HPN Cartridge to Chinese regulatory authority NMPA includes U.S. and EU data Leverages recent changes in [...]
Sanofi: CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
04/02/2019
CHMP recommends approval of Praluent ® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease PARIS and TARRYTOWN, NY - February 4, 2019 - The European Medicines [...]
Sanofi : Le CHMP recommande l'approbation de Praluent® (alirocumab) pour la réduction du risque cardiovasculaire chez les personnes atteintes de maladie cardiovasculaire athéroscléreuse établie
04/02/2019
Le CHMP recommande l'approbation de Praluent ® (alirocumab) pour la réduction du risque cardiovasculaire chez les personnes atteintes de maladie cardiovasculaire athéroscléreuse établie Paris et Tarrytown (New York) - [...]

Pages